Related Experiment Video

Updated: May 14, 2026

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell

C Zielinski1, S Knapp, C Mascaux

  • 1Central European Cooperative Oncology Group (CECOG), Vienna, Vienna General Hospital, Vienna, Austria. christoph.zielinski@meduniwien.ac.at

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|February 9, 2013
PubMed
Abstract

Insights

Immunotherapy targeting CTLA-4 and PD-1 shows promise for non-small-cell lung cancer (NSCLC). Combining checkpoint blockade with chemotherapy is effective for squamous NSCLC.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Research

Background:

  • Non-small-cell lung cancer (NSCLC), especially squamous NSCLC, has limited treatment options.
  • The tumor microenvironment in NSCLC presents opportunities for immunomodulatory therapies.
  • Targeting immune checkpoints like CTLA-4 and PD-1 offers a novel therapeutic strategy.

Purpose of the Study:

  • To review the immunomodulatory environment in NSCLC.
  • To explore the potential of targeting the cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1) pathways.
  • To assess the clinical benefit of immune checkpoint blockade in NSCLC.

Main Methods:

  • Literature search of PubMed and presented abstracts.
  • Review of studies on clinical benefit of checkpoint blockade in NSCLC.
  • Analysis of clinical trial data for anti-CTLA-4 and anti-PD-1 antibodies.

Main Results:

  • Antibody-mediated blockade of CTLA-4 (ipilimumab) and PD-1 (nivolumab) is under investigation for NSCLC.
  • Ipilimumab showed efficacy in advanced squamous NSCLC when combined with chemotherapy in a Phase II study.
  • Nivolumab demonstrated activity in both squamous and non-squamous NSCLC in a Phase I study.
  • Ongoing Phase III trials are evaluating the therapeutic potential of these agents.

Conclusions:

  • Understanding NSCLC immunity has led to the development of checkpoint blockade immunotherapeutics.
  • Clinical evidence supports combining checkpoint blockade with chemotherapy for squamous NSCLC.
  • Further research and clinical trials are essential to establish the role of these therapies in NSCLC treatment.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.